Revolution Medicines' stock has surged over 30% since April, driven by promising clinical data for its lead asset, RMC-6236, targeting RAS-mutated cancers. RMC-6236 shows best-in-class efficacy in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback